MedPage Today on MSN
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer: A Common Clinical Challenge
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, ...
MedPage Today on MSN
For Your Patients: Next Steps If There Is Resistance to Endocrine Therapy
When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...
A new research paper was published in Volume 17, Issue 8 of Aging-US on August 7, 2025, titled, “What is the clinical ...
In phase 2 results, bimiralisib gel 2% demonstrated high efficacy and tolerability in treating actinic keratosis, achieving a ...
A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The ...
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study A total of 3.4% (41/1,206) of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback